Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 72 entries
Sorted by: Best Match Show Resources per page
Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop.

The Journal of rheumatology

Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, Kwoh K, Maxwell LJ, Moore A, Singh JA, Stevens R, Strand V, Suarez-Almazor ME, Tugwell P, Wells GA.
PMID: 25979719
J Rheumatol. 2015 Oct;42(10):1962-1970. doi: 10.3899/jrheum.141440. Epub 2015 May 15.

OBJECTIVE: Pain is a patient-important outcome, but current reporting in randomized controlled trials and systematic reviews is often suboptimal, impeding clinical interpretation and decision making.METHODS: A working group at the 2014 Outcome Measures in Rheumatology (OMERACT 12) was convened...

Cite
Busse JW, Bartlett SJ, Dougados M, et al. Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. J Rheumatol. 2015;42(10):1962-1970doi: 10.3899/jrheum.141440.
Busse, J. W., Bartlett, S. J., Dougados, M., Johnston, B. C., Guyatt, G. H., Kirwan, J. R., Kwoh, K., Maxwell, L. J., Moore, A., Singh, J. A., Stevens, R., Strand, V., Suarez-Almazor, M. E., Tugwell, P., & Wells, G. A. (2015). Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. The Journal of rheumatology, 42(10), 1962-1970. https://doi.org/10.3899/jrheum.141440
Busse, Jason W, et al. "Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop." The Journal of rheumatology vol. 42,10 (2015): 1962-1970. doi: https://doi.org/10.3899/jrheum.141440
Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, Kwoh K, Maxwell LJ, Moore A, Singh JA, Stevens R, Strand V, Suarez-Almazor ME, Tugwell P, Wells GA. Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. J Rheumatol. 2015 Oct;42(10):1962-1970. doi: 10.3899/jrheum.141440. Epub 2015 May 15. PMID: 25979719.
Copy Download .nbib Format: NLM
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.

RMD open

Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, Cantagrel A, Dougados M, Andres E, Meyer O, Carli P, Pertuiset E, Pane I, Maurier F, Ravaud P, Mariette X, Gottenberg JE.
PMID: 26509060
RMD Open. 2015 Jun 30;1(1):e000034. doi: 10.1136/rmdopen-2014-000034. eCollection 2015.

OBJECTIVES: To evaluate the prevalence of late-onset neutropenia and its complications in patients treated with rituximab (RTX) for rheumatoid arthritis (RA) and other autoimmune diseases (AIDs) in a prospective registry.METHODS: The AutoImmunity and Rituximab registry is an independent 7-year...

Cite
Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):e000034doi: 10.1136/rmdopen-2014-000034.
Salmon, J. H., Cacoub, P., Combe, B., Sibilia, J., Pallot-Prades, B., Fain, O., Cantagrel, A., Dougados, M., Andres, E., Meyer, O., Carli, P., Pertuiset, E., Pane, I., Maurier, F., Ravaud, P., Mariette, X., & Gottenberg, J. E. (2015). Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD open, 1(1), e000034. https://doi.org/10.1136/rmdopen-2014-000034
Salmon, J H, et al. "Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry." RMD open vol. 1,1 (2015): e000034. doi: https://doi.org/10.1136/rmdopen-2014-000034
Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, Cantagrel A, Dougados M, Andres E, Meyer O, Carli P, Pertuiset E, Pane I, Maurier F, Ravaud P, Mariette X, Gottenberg JE. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015 Jun 30;1(1):e000034. doi: 10.1136/rmdopen-2014-000034. eCollection 2015. PMID: 26509060; PMCID: PMC4612695.
Copy Download .nbib Format: NLM
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.

RMD open

Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M.
PMID: 28405473
RMD Open. 2017 Mar 21;3(1):e000410. doi: 10.1136/rmdopen-2016-000410. eCollection 2017.

OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs.METHODS: In this phase III study, patients were randomised 1:1:1...

Cite
Emery P, Blanco R, Maldonado Cocco J, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017;3(1):e000410doi: 10.1136/rmdopen-2016-000410.
Emery, P., Blanco, R., Maldonado Cocco, J., Chen, Y. C., Gaich, C. L., DeLozier, A. M., de Bono, S., Liu, J., Rooney, T., Chang, C. H., & Dougados, M. (2017). Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD open, 3(1), e000410. https://doi.org/10.1136/rmdopen-2016-000410
Emery, Paul, et al. "Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis." RMD open vol. 3,1 (2017): e000410. doi: https://doi.org/10.1136/rmdopen-2016-000410
Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017 Mar 21;3(1):e000410. doi: 10.1136/rmdopen-2016-000410. eCollection 2017. PMID: 28405473; PMCID: PMC5372156.
Copy Download .nbib Format: NLM
CD26/DPPIV and response to hepatitis B vaccination.

Pathophysiology : the official journal of the International Society for Pathophysiology

Dourado M, Alves V, Mesquita L, Ramos I, Pinto AM, Rosa MS.
PMID: 15561511
Pathophysiology. 2004 Dec;11(3):147-152. doi: 10.1016/j.pathophys.2004.06.002.

The prevention of hepatitis B is important, since it is responsible for significant morbidity and mortality around the world. Unfortunately, hepatitis B vaccine does not always induce protective immunity. The lack of immune response to vaccine (non-responders) can depend...

Cite
Dourado M, Alves V, Mesquita L, et al. CD26/DPPIV and response to hepatitis B vaccination. Pathophysiology. 2004;11(3):147-152doi: 10.1016/j.pathophys.2004.06.002.
Dourado, M., Alves, V., Mesquita, L., Ramos, I., Pinto, A. M., & Rosa, M. S. (2004). CD26/DPPIV and response to hepatitis B vaccination. Pathophysiology : the official journal of the International Society for Pathophysiology, 11(3), 147-152. https://doi.org/10.1016/j.pathophys.2004.06.002
Dourado, Marília, et al. "CD26/DPPIV and response to hepatitis B vaccination." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 11,3 (2004): 147-152. doi: https://doi.org/10.1016/j.pathophys.2004.06.002
Dourado M, Alves V, Mesquita L, Ramos I, Pinto AM, Rosa MS. CD26/DPPIV and response to hepatitis B vaccination. Pathophysiology. 2004 Dec;11(3):147-152. doi: 10.1016/j.pathophys.2004.06.002. PMID: 15561511.
Copy Download .nbib Format: NLM
MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)'.

RMD open

Lukas C, Cyteval C, Dougados M, Weber U.
PMID: 29479474
RMD Open. 2018 Jan 12;4(1):e000586. doi: 10.1136/rmdopen-2017-000586. eCollection 2018.

Recognition of axial spondyloarthritis (SpA) remains challenging, as no unique reference standard is available to ascertain diagnosis. Imaging procedures have been used for long in the field, in particular pelvic radiography, to capture structural changes evocative of sacroiliitis, the...

Cite
Lukas C, Cyteval C, Dougados M, et al. MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)'. RMD Open. 2018;4(1):e000586doi: 10.1136/rmdopen-2017-000586.
Lukas, C., Cyteval, C., Dougados, M., & Weber, U. (2018). MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)'. RMD open, 4(1), e000586. https://doi.org/10.1136/rmdopen-2017-000586
Lukas, Cédric, et al. "MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)'." RMD open vol. 4,1 (2018): e000586. doi: https://doi.org/10.1136/rmdopen-2017-000586
Lukas C, Cyteval C, Dougados M, Weber U. MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)'. RMD Open. 2018 Jan 12;4(1):e000586. doi: 10.1136/rmdopen-2017-000586. eCollection 2018. PMID: 29479474; PMCID: PMC5822619.
Copy Download .nbib Format: NLM
Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR.

Joint bone spine

Wendling D, Prati C, Saraux A, Molto A, Pham T, Dougados M, Guillot X.
PMID: 31958574
Joint Bone Spine. 2020 Oct;87(5):497-499. doi: 10.1016/j.jbspin.2020.01.003. Epub 2020 Jan 17.

No abstract available.

Cite
Wendling D, Prati C, Saraux A, et al. Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. Joint Bone Spine. 2020;87(5):497-499doi: 10.1016/j.jbspin.2020.01.003.
Wendling, D., Prati, C., Saraux, A., Molto, A., Pham, T., Dougados, M., & Guillot, X. (2020). Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. Joint bone spine, 87(5), 497-499. https://doi.org/10.1016/j.jbspin.2020.01.003
Wendling, Daniel, et al. "Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR." Joint bone spine vol. 87,5 (2020): 497-499. doi: https://doi.org/10.1016/j.jbspin.2020.01.003
Wendling D, Prati C, Saraux A, Molto A, Pham T, Dougados M, Guillot X. Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. Joint Bone Spine. 2020 Oct;87(5):497-499. doi: 10.1016/j.jbspin.2020.01.003. Epub 2020 Jan 17. PMID: 31958574.
Copy Download .nbib Format: NLM
Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life.

RMD open

Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A.
PMID: 30487997
RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018.

OBJECTIVE: The goal of managing axial spondyloarthritis (axSpA) is to improve and maintain patients' health-related quality of life (HRQoL), mainly through targeting towards low disease activity. Here, we aim to gain insight into the joint evolution of HRQoL and...

Cite
Imkamp M, Lima Passos V, Boonen A, et al. Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open. 2018;4(2):e000755doi: 10.1136/rmdopen-2018-000755.
Imkamp, M., Lima Passos, V., Boonen, A., Arends, S., Dougados, M., Landewé, R., Ramiro, S., Van den Bosch, F., van der Heijde, D., Wink, F. R., Spoorenberg, A., & van Tubergen, A. (2018). Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD open, 4(2), e000755. https://doi.org/10.1136/rmdopen-2018-000755
Imkamp, Maike, et al. "Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life." RMD open vol. 4,2 (2018): e000755. doi: https://doi.org/10.1136/rmdopen-2018-000755
Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A. Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018. PMID: 30487997; PMCID: PMC6241970.
Copy Download .nbib Format: NLM
Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

RMD open

Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A.
PMID: 30564453
RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018.

OBJECTIVE: To investigate the occurrence of ankylosing spondylitis (AS)-related sick leave (SL) over 6 12 years and explore factors predicting first and recurrent SL.METHODS: Data from employed patients from the Outcome in Ankylosing Spondylitis International Study were used. At...

Cite
Webers C, Ramiro S, Landewé R, et al. Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open. 2018;4(2):e000766doi: 10.1136/rmdopen-2018-000766.
Webers, C., Ramiro, S., Landewé, R., van der Heijde, D., van den Bosch, F., Dougados, M., van Tubergen, A., & Boonen, A. (2018). Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD open, 4(2), e000766. https://doi.org/10.1136/rmdopen-2018-000766
Webers, Casper, et al. "Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study." RMD open vol. 4,2 (2018): e000766. doi: https://doi.org/10.1136/rmdopen-2018-000766
Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A. Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018. PMID: 30564453; PMCID: PMC6269643.
Copy Download .nbib Format: NLM
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.

Annals of the rheumatic diseases

Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L, Szekanecz Z, Choy EH, Dougados M, Jacobs JW, Geenen R, Bijlsma JW, Zink A, Aletaha D, Schoneveld L, van Riel P, Dumas S, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM.
PMID: 34407926
Ann Rheum Dis. 2022 Jan;81(1):20-33. doi: 10.1136/annrheumdis-2021-220973. Epub 2021 Aug 18.

OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA).METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology...

Cite
Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;81(1):20-33doi: 10.1136/annrheumdis-2021-220973.
Nagy, G., Roodenrijs, N. M. T., Welsing, P. M. J., Kedves, M., Hamar, A., van der Goes, M. C., Kent, A., Bakkers, M., Pchelnikova, P., Blaas, E., Senolt, L., Szekanecz, Z., Choy, E. H., Dougados, M., Jacobs, J. W., Geenen, R., Bijlsma, J. W., Zink, A., Aletaha, D., Schoneveld, L., van Riel, P., Dumas, S., Prior, Y., Nikiphorou, E., Ferraccioli, G., Schett, G., Hyrich, K. L., Mueller-Ladner, U., Buch, M. H., McInnes, I. B., van der Heijde, D., & van Laar, J. M. (2022). EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the rheumatic diseases, 81(1), 20-33. https://doi.org/10.1136/annrheumdis-2021-220973
Nagy, György, et al. "EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis." Annals of the rheumatic diseases vol. 81,1 (2022): 20-33. doi: https://doi.org/10.1136/annrheumdis-2021-220973
Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L, Szekanecz Z, Choy EH, Dougados M, Jacobs JW, Geenen R, Bijlsma JW, Zink A, Aletaha D, Schoneveld L, van Riel P, Dumas S, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022 Jan;81(1):20-33. doi: 10.1136/annrheumdis-2021-220973. Epub 2021 Aug 18. PMID: 34407926.
Copy Download .nbib Format: NLM
Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic.

The Lancet. Rheumatology

Dougados M.
PMID: 33786453
Lancet Rheumatol. 2021 Jun;3(6):e395-e396. doi: 10.1016/S2665-9913(21)00077-1. Epub 2021 Mar 25.

No abstract available.

Cite
Dougados M. Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic. Lancet Rheumatol. 2021;3(6):e395-e396doi: 10.1016/S2665-9913(21)00077-1.
Dougados, M. (2021). Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic. The Lancet. Rheumatology, 3(6), e395-e396. https://doi.org/10.1016/S2665-9913(21)00077-1
Dougados, Maxime. "Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic." The Lancet. Rheumatology vol. 3,6 (2021): e395-e396. doi: https://doi.org/10.1016/S2665-9913(21)00077-1
Dougados M. Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic. Lancet Rheumatol. 2021 Jun;3(6):e395-e396. doi: 10.1016/S2665-9913(21)00077-1. Epub 2021 Mar 25. PMID: 33786453; PMCID: PMC7993927.
Copy Download .nbib Format: NLM
The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism

Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D.
PMID: 34489113
Semin Arthritis Rheum. 2021 Aug 01; doi: 10.1016/j.semarthrit.2021.07.021. Epub 2021 Aug 01.

BACKGROUND: The current core outcome set for ankylosing spondylitis (AS) has had only minor adaptations since its development 20 years ago. Considering the significant advances in this field during the preceding decades, an update of this core set is...

Cite
Navarro-Compán V, Boel A, Boonen A, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021;doi: 10.1016/j.semarthrit.2021.07.021.
Navarro-Compán, V., Boel, A., Boonen, A., Mease, P., Landewé, R., Kiltz, U., Dougados, M., Baraliakos, X., Bautista-Molano, W., Carlier, H., Chiowchanwisawakit, P., Dagfinrud, H., de Peyrecave, N., El-Zorkany, B., Fallon, L., Gaffney, K., Garrido-Cumbrera, M., Gensler, L. S., Haroon, N., Kwan, Y. H., Machado, P. M., Maksymowych, W. P., Poddubnyy, D., Protopopov, M., Ramiro, S., Shea, B., Song, I. H., van Weely, S., & van der Heijde, D. (2021). The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in arthritis and rheumatism, . https://doi.org/10.1016/j.semarthrit.2021.07.021
Navarro-Compán, V, et al. "The ASAS-OMERACT core domain set for axial spondyloarthritis." Seminars in arthritis and rheumatism vol. (2021). doi: https://doi.org/10.1016/j.semarthrit.2021.07.021
Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021 Aug 01; doi: 10.1016/j.semarthrit.2021.07.021. Epub 2021 Aug 01. PMID: 34489113.
Copy Download .nbib Format: NLM
Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng.

Annals of the rheumatic diseases

Molto A, van der Heijde D, Van den Bosch FE, Dougados M.
PMID: 34187778
Ann Rheum Dis. 2021 Jun 29; doi: 10.1136/annrheumdis-2021-220913. Epub 2021 Jun 29.

No abstract available.

Cite
Molto A, van der Heijde D, Van den Bosch FE, et al. Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-220913.
Molto, A., van der Heijde, D., Van den Bosch, F. E., & Dougados, M. (2021). Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-220913
Molto, Anna, et al. "Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-220913
Molto A, van der Heijde D, Van den Bosch FE, Dougados M. Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng. Ann Rheum Dis. 2021 Jun 29; doi: 10.1136/annrheumdis-2021-220913. Epub 2021 Jun 29. PMID: 34187778.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 72 entries